Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24731558 | 0.86 | — | — | |
| SCHEMBL30083148 | 0.86 | — | — | |
| SCHEMBL24731563 | 0.86 | — | — | |
| SCHEMBL3114419 | 0.85 | ROCK2 (0.50) | MAPK1MAPK3ROCK2RPS6KA5MAP4K4 | |
| SCHEMBL3098714 | 0.85 | MEN1 (0.61) | MAPK1MEN1KMT2AROCK2RPS6KA5 | |
| SCHEMBL3104517 | 0.85 | MEN1 (0.61) | MAPK1MEN1KMT2AROCK2RPS6KA5 | |
| SCHEMBL3108847 | 0.84 | ROCK2 (0.66) | MAPK1MAPK3PDE2ALMNAGAA | |
| SCHEMBL3103502 | 0.84 | ROCK2 (0.66) | MAPK1MAPK3PDE2ALMNAGAA | |
| SCHEMBL3104350 | 0.84 | SMN1; SMN2 (0.52) | MAPK1MAPK3MEN1KMT2AROCK2 | |
| SCHEMBL3112357 | 0.84 | SMN1; SMN2 (0.52) | MAPK1MAPK3MEN1KMT2AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105386-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND (DE) | 2015-04-16 | — | — | US | disclosed |
| US-8895749-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130310378-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8445686-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100273828-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310378-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | MAPK1 786/4885MAPK3 221/4885MEN1 4364/4885 |
| US-20150105386-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | MAPK1 786/4885MAPK3 217/4885MEN1 4369/4885 |
| US-20100273828-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | MAPK1 786/4885MAPK3 221/4885MEN1 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.